Immunotherapy: Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

(2016) R. Gardner et al.   BLOOD

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

(2016) Marco Ruella et al.   JOURNAL OF CLINICAL INVESTIGATION

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

(2016) Eric Tran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy

(2016) Ahmad Rayes et al.   PEDIATRIC BLOOD & CANCER

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity

(2016) Elad Jacoby et al.   Nature Communications

Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells

(2015) Andrew G. Evans et al.   BRITISH JOURNAL OF HAEMATOLOGY

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

(2015) E. Sotillo et al.   Cancer Discovery

Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients

(2014) E. Cha et al.   Science Translational Medicine